HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
WAC
WW domain containing adaptor with coiled-coil
Chromosome 10 Β· 10p12.1|10p12.1-p11.2
NCBI Gene: 51322Ensembl: ENSG00000095787.27HGNC: HGNC:17327UniProt: Q9BTA9
91PubMed Papers
21Diseases
0Drugs
112Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedTranscription Factor
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
RNA polymerase II complex bindingchromatin bindingprotein bindingchromatin remodeling10p11.21p12.31 microdeletion syndromeDeSanto-Shinawi syndrome due to WAC point mutationDeSanto-Shinawi syndromegenetic disorder
✦AI Summary

WAC (WW domain containing adaptor with coiled-coil) is a multifunctional regulatory protein that bridges transcriptional and post-translational processes. Structurally, WAC contains a WW domain that interacts with RNA polymerase II transcriptional machinery and a coiled-coil region that binds the RNF20-RNF40 ubiquitin ligase complex, thereby coupling histone H2B monoubiquitination at lysine 120 to active gene transcription 1. Beyond transcriptional regulation, WAC functions as a metabolic checkpoint protein that positively regulates mTORC1 signaling by promoting assembly of the TTT-RUVBL complex in an energy-dependent manner, while also acting as a selective autophagy regulatorβ€”promoting amino acid starvation-induced autophagy while suppressing basal autophagy 23. Recently, WAC was shown to facilitate mesenchymal stem cell osteogenesis by protecting PINK1 from ubiquitination-dependent degradation, thereby activating mitophagy and promoting new bone formation, with reduced WAC levels observed in osteoporosis patients 4. WAC regulates DNA damage checkpoint responses 1 and may negatively regulate proteasomal protein degradation. Pathologically, de novo mutations in WAC have been identified in moderate-to-severe intellectual disability cases 5, and WAC-AS1, its antisense RNA, shows aberrant expression correlating with immune infiltration and poor prognosis across multiple cancer types 6.

Sources cited
1
WAC links transcription to H2BK120ub1 via WW domain-RNA Pol II and coiled-coil-RNF20/40 interactions; regulates DNA damage checkpoints
PMID: 21329877
2
WAC positively regulates amino acid starvation-induced autophagy
PMID: 22354037
3
WAC positively regulates mTORC1 activity via TTT-RUVBL complex assembly and negatively regulates basal autophagy
PMID: 26812014
4
WAC promotes MSC osteogenesis by protecting PINK1 from ubiquitination, activating mitophagy; reduced in osteoporosis
PMID: 39555688
5
De novo WAC mutations identified as possibly pathogenic in moderate-to-severe intellectual disability cases
PMID: 25356899
6
WAC-AS1 lncRNA shows aberrant expression correlating with immune infiltration and poor prognosis across multiple cancer types
PMID: 37248547
Disease Associationsβ“˜21
10p11.21p12.31 microdeletion syndromeOpen Targets
0.74Strong
DeSanto-Shinawi syndrome due to WAC point mutationOpen Targets
0.73Strong
DeSanto-Shinawi syndromeOpen Targets
0.61Moderate
genetic disorderOpen Targets
0.49Moderate
Intellectual disabilityOpen Targets
0.49Moderate
Neurodevelopmental disorderOpen Targets
0.41Moderate
Neurodevelopmental delayOpen Targets
0.34Weak
Neurodevelopmental abnormalityOpen Targets
0.34Weak
glomerulonephritisOpen Targets
0.32Weak
Sensorineural hearing impairmentOpen Targets
0.31Weak
COVID-19Open Targets
0.31Weak
ovarian carcinomaOpen Targets
0.31Weak
heart diseaseOpen Targets
0.28Weak
ovarian dysfunctionOpen Targets
0.26Weak
Rare genetic intellectual disabilityOpen Targets
0.26Weak
multiple myelomaOpen Targets
0.25Weak
gastritisOpen Targets
0.23Weak
congenital anomaly of cardiovascular systemOpen Targets
0.22Weak
autonomic nervous system diseaseOpen Targets
0.11Weak
humerus fractureOpen Targets
0.10Weak
DeSanto-Shinawi syndromeUniProt
Pathogenic Variants112
NM_016628.5(WAC):c.1437+1G>APathogenic
DeSanto-Shinawi syndrome due to WAC point mutation|not provided|Shwachman syndrome
β˜…β˜…β˜†β˜†2026
NM_016628.5(WAC):c.302C>G (p.Ser101Ter)Pathogenic
DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜…β˜†β˜†2025β†’ Residue 101
NM_016628.5(WAC):c.381+1G>TLikely pathogenic
DeSanto-Shinawi syndrome due to WAC point mutation|not provided
β˜…β˜…β˜†β˜†2025
NM_016628.5(WAC):c.1161_1164del (p.Asn387fs)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 387
NM_016628.5(WAC):c.670_673del (p.Thr224fs)Pathogenic
not provided|DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜…β˜†β˜†2025β†’ Residue 224
NM_016628.5(WAC):c.1648C>T (p.Arg550Ter)Pathogenic
DeSanto-Shinawi syndrome due to WAC point mutation|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2025β†’ Residue 550
NM_016628.5(WAC):c.577C>T (p.Gln193Ter)Pathogenic
not provided|DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜…β˜†β˜†2025β†’ Residue 193
NM_016628.5(WAC):c.139C>T (p.Arg47Ter)Pathogenic
not provided|DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜…β˜†β˜†2025β†’ Residue 47
NM_016628.5(WAC):c.1837C>T (p.Arg613Ter)Pathogenic
not provided|DeSanto-Shinawi syndrome due to WAC point mutation|Neurodevelopmental abnormality|Intellectual disability
β˜…β˜…β˜†β˜†2024β†’ Residue 613
NM_016628.5(WAC):c.255_256del (p.Arg85fs)Pathogenic
not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 85
NM_016628.5(WAC):c.1537C>T (p.Arg513Ter)Pathogenic
DeSanto-Shinawi syndrome due to WAC point mutation|not provided
β˜…β˜…β˜†β˜†2024β†’ Residue 513
NM_016628.5(WAC):c.1864C>T (p.Arg622Ter)Pathogenic
not provided|DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜…β˜†β˜†2024β†’ Residue 622
NM_016628.5(WAC):c.1746+2T>CPathogenic
Neurodevelopmental delay|not provided
β˜…β˜…β˜†β˜†2024
NM_016628.5(WAC):c.508C>T (p.Gln170Ter)Pathogenic
WAC-related neurodevelopmental disorder|DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜…β˜†β˜†2024β†’ Residue 170
NM_016628.5(WAC):c.1346C>G (p.Ser449Ter)Pathogenic
not provided|DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜…β˜†β˜†2024β†’ Residue 449
NM_016628.5(WAC):c.263_266del (p.Glu88fs)Pathogenic
DeSanto-Shinawi syndrome due to WAC point mutation|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2023β†’ Residue 88
NM_016628.5(WAC):c.310del (p.His104fs)Pathogenic
not provided|DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜…β˜†β˜†2023β†’ Residue 104
NM_016628.5(WAC):c.451C>T (p.Arg151Ter)Pathogenic
not provided|Rare genetic intellectual disability|DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜…β˜†β˜†2023β†’ Residue 151
NM_016628.5(WAC):c.1198C>T (p.Gln400Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2022β†’ Residue 400
NM_016628.5(WAC):c.466C>T (p.Gln156Ter)Pathogenic
DeSanto-Shinawi syndrome due to WAC point mutation
β˜…β˜†β˜†β˜†2025β†’ Residue 156
View on ClinVar β†—
Related Genes
RNF20Protein interaction100%UBE2AProtein interaction96%RNF40Protein interaction96%CDC5LProtein interaction83%CBX3Shared pathway25%CHD1LShared pathway25%
Tissue Expression6 tissues
Bone Marrow
100%
Brain
70%
Heart
59%
Ovary
51%
Lung
49%
Liver
32%
Gene Interaction Network
Click a node to explore
WACRNF20UBE2ARNF40CDC5LCBX3CHD1L
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q9BTA9
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.25Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.15 [0.09–0.25]
RankingsWhere WAC stands among ~20K protein-coding genes
  • #5,281of 20,598
    Most Researched91
  • #701of 5,498
    Most Pathogenic Variants112 Β· top quartile
  • #751of 17,882
    Most Constrained (LOEUF)0.25 Β· top 5%
Genes detectedWAC
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Type 2 immunity in allergic diseases.
PMID: 39962262
Cell Mol Immunol Β· 2025
1.00
2
Menstrual cycle rhythmicity: metabolic patterns in healthy women.
PMID: 30275458
Sci Rep Β· 2018
0.90
3
Advanced Imaging for Acute Stroke Treatment Selection: CT, CTA, CT Perfusion, and MR Imaging.
PMID: 36931761
Radiol Clin North Am Β· 2023
0.80
4
WAC Facilitates Mitophagy-mediated MSC Osteogenesis and New Bone Formation via Protecting PINK1 from Ubiquitination-Dependent Degradation.
PMID: 39555688
Adv Sci (Weinh) Β· 2025
0.70
5
De novo mutations in moderate or severe intellectual disability.
PMID: 25356899
PLoS Genet Β· 2014
0.60